Von der Apotheke zum Weltmarktführer - Vetter im ... - Vetter Pharma

Das Executive Committee (von links nach rechts):
Udo J. Vetter, Gunther Strothe und Wolfgang Kerkhoff
The Executive Committee (from left to right):
Udo J. Vetter, Gunther Strothe and Wolfgang Kerkhoff
Since January 1, 2008, the company trustees have been
Gunther Strothe and Wolfgang Kerkhoff. The political economist
Gunther Strothe is a financial expert with international
experience. From 1995 to 2006, he set up the German operations
of the international Oliver Wyman global management
consultancy. In addition, he is on the Board of Supervisors of
Germany’s largest independent service provider for private real
estate financing. He joined the company in 1983 together with
Jenik Radon via Vetter Pharma-Turm Inc. and supported the
sales subsidiary in the USA as an auditor until 1990. Wolfgang
Kerkhoff is a senior partner in the renowned Munich congress
agency EUROKONGRESS. He is active in various international
associations and gives lectures at Munich’s university.
Vetter also convened a council of independent experts at
the beginning of the year 2008 to act as an advisory body for
management. It is made up of the trustees, representatives from
business and members of the Vetter family.
After some comprehensive structural changes at the beginning
of the new millennium, the company is now being led as
a modern organization and with clear corporate governance
guidelines while maintaining the testamentary stipulations
of Helmut Vetter. For the new trustees Gunther Strothe and
Wolfgang Kerkhoff, maintaining this continuity will represent
an important task.
Another guarantee for the continuity of the company is the
unified strategy of the three Vetter families. Udo J. Vetter in particular,
who has been involved in the international pharmaceutical
industry since the mid-1970s and has been working with the
company since 1983, has been actively contributing his over 30
years’ worth of experience in pharmaceuticals.
At the beginning of 2008, Vetter received the first approval
for the filling of a drug at the RVS facility. Permission from the
US regulatory agency FDA was a crowning success for the largest
investment in the company’s history. With it, Vetter underscored
its broad competencies in the manufacturing of aseptic
prefilled injection systems. It was a success that was rooted not
least in the many years of know-how in the construction of
aseptic facilities and was achieved, too, by close collaboration
with the »Regierungspräsidium« Tübingen and the FDA during
the conception stage.
At this point in time, the construction of the visual inspection
and secondary packaging building in Ravensburg-Mariatal
was right on schedule. By May 2008, the façade was complete
and work on the interior could begin. From August 2008 till the
beginning of 2009, the packaging lines were gradually built and
put into commission. A total of 20 million euros was invested
in the new construction, which was mostly built with partners
from the region. The project was another cornerstone in assuring
the company’s future and was realized within the context of
growing customer requests for solutions in the rising homecare
sector. Thus, pen systems and autoinjectors can also be
processed in Mariatal and prefilled syringes with safety devices
to prevent needlestick injuries are also an option here in view of
new regulations issued by the authorities.
98 …